Pretreatment of Epithelial Cells with Rifaximin Alters Bacterial Attachment and Internalization Profiles
Authors:
- 1 January 2010
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 54 (1) , 388-396
Abstract
Rifaximin is a poorly absorbed semisynthetic antibiotic derivative of rifampin licensed for use in the treatment of traveler's diarrhea. Rifaximin reduces the symptoms of enteric infection, often without pathogen eradication and with limited effects on intestinal flora. Epithelial cells (HEp-2 [laryngeal], HCT-8 [ileocecal], A549 [lung], and HeLa [cervical]) were pretreated with rifaximin (or control antibiotics) prior to the addition of enteroaggregative Escherichia coli (EAEC). EAEC adherence was significantly reduced following rifaximin pretreatment compared to pretreatment with rifampin or doxycycline for three of the four cell lines tested. The rifaximin-mediated changes to epithelial cells were explored further by testing the attachment and internalization of either Bacillus anthracis or Shigella sonnei into A549 or HeLa cells, respectively. The attachment and internalization of B. anthracis were significantly reduced following rifaximin pretreatment. In contrast, neither the attachment nor the internalization of S. sonnei was affected by rifaximin pretreatment of HeLa cells, suggesting that rifaximin-mediated modulation of host cell physiology affected bacteria utilizing distinct attachment/internalization mechanisms differently. In addition, rifaximin pretreatment of HEp-2 cells led to reduced concentrations of inflammatory cytokines from uninfected cells. The study provides evidence that rifaximin-mediated changes in epithelial cell physiology are associated with changes in bacterial attachment/internalization and reduced inflammatory cytokine release.Keywords
This publication has 29 references indexed in Scilit:
- Involvement of central immunity in uncomplicated diverticular diseaseScandinavian Journal of Gastroenterology, 2009
- Potential dissemination of Bacillus anthracis utilizing human lung epithelial cellsCellular Microbiology, 2008
- Virulence characteristics and the molecular epidemiology of enteroaggregative Escherichia coli isolates from travellers to developing countriesJournal of Medical Microbiology, 2007
- Rifaximin versus Other Antibiotics in the Primary Treatment and Retreatment of Bacterial Overgrowth in IBSDigestive Diseases and Sciences, 2007
- Bacillus anthracis internalization by human fibroblasts and epithelial cellsCellular Microbiology, 2007
- Hospitalizations During the Use of Rifaximin Versus Lactulose for the Treatment of Hepatic EncephalopathyDigestive Diseases and Sciences, 2007
- Rifaximin: A Novel Nonabsorbed Rifamycin for Gastrointestinal DisordersClinical Infectious Diseases, 2006
- Interaction of Rifalazil with Oxidant-Generating Systems of Human Polymorphonuclear NeutrophilsAntimicrobial Agents and Chemotherapy, 2005
- Interleukin-8 Response in an Intestinal HCT-8 Cell Line Infected with Enteroaggregative and Enterotoxigenic Escherichia coliClinical and Vaccine Immunology, 2004
- In Vitro Activity and Fecal Concentration of Rifaximin after Oral AdministrationAntimicrobial Agents and Chemotherapy, 2000